WST raises full-year guidance after strong Q2
West Pharmaceutical’s Q2 revenue grew 13%, driven by HVP and GLP-1 demand, leading it to raise its full-year outlook.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.